Critical Care Guidelines FOR CRITICAL CARE USE ONLY

Liver Transplant Patients

Key early management issues:

- 1. Potential for bleeding
- 2. Intravascular Volume requirement -

Intraoperative course/pre-existing ascites/ongoing drain losses may predict those who require lots of fluid. Frequent clinical and biochemical assessment crucial.

3. Assessment of early graft function-

Clinical/biochemical/haematological/acid base and radiological assessment (Doppler in 1st 24hrs organised by transplant team)

First 24hrs

On arrival from theatre patient admitted in the routine fashion.

On Admission:

ABC- as for any ventilated ICU admission

Immediate establishment of monitoring (see below)

Sedation- Patients arrive from theatre sedated and ventilated (see drugs below) **Bloods-** see dedicated liver transplant results flow sheet for first 24hrs tests/times **Paperwork-** medical and nursing admission, drug kardex, fluids, audit form

Lines:

Arterial x 2- transducer both waveforms

IJ Vein x 2- 1 CVP monitoring

1 rapid infusion line (minimise use, not for vasoactive drugs) PA catheter must be continuously transduced and displayed (if present). Ensure obturator in place when removed

NG tube- on free drainage

Urinary catheter Surgical drains

Drugs:

1. Antibiotics-

Co-amoxiclav 1.2 grams at 0 and 8 hours from start of operation Metronidazole 500mg at 0 and 8 hours from start of operation (if roux-en-Y) **Penicillin Allergic:**

Cipro 400mg at 0 and 12 hours from start of operation

Vanc 1g at 0 hours and review 2nd dose at 12 hours

Metronidazole 500mg at 0 and 8 hours from start of operation (if roux-en-Y)

(NB. check what antibiotics given in theatre)

- 2. Fluconazole 100mg iv daily
- 3. Ranitidine- 50mg iv tid
- 4. Sedation- Propofol and Alfentanil

Morphine/Fentanyl PCA when extubated

Title: Liver Transplant Patients	
	Authors: D Cameron, C Beattie
Status Draft/Final: FINAL	Approved by: QIT editorial group
	Written: Aug 15
Reviewed on:	Next review: Aug 2018

Critical Care Guidelines FOR CRITICAL CARE USE ONLY

5. Immunosuppression: see appendix

PATIENTS SHOULD ARRIVE FROM THEATRE WITH INITIAL IMMUNOSUPPRESSION PATHWAY DOCUMENTED IN HANDOVER.

All Patients:

Hydrocortisone 100mg iv bd PLUS

Tacrolimus/Azathioprine OR Basiliximab/MMF

6. Hepatitis B Patients:

Human Hepatitis B Immunoglobulin- see instructions in Pharmacy Folder

Ongoing management

General condition and stability will dictate speed of weaning, extubation and deescalation of monitoring.

Biochemical (falling lactate) and haematological (falling/stable prothrombin time) markers of acceptable graft function.

Lines should not be removed until radiological confirmation of graft perfusion. Assess coagulopathy/low platelets- D/W Consultant prior to correction/line removal

Common pitfalls are failure to recognise hypovolaemia. Consider in presence of rising lactate and inappropriate or persistently rising doses of noradrenaline.

Discharge to transplant HDU:

Liaise with HDU nursing and medical staff Lines: 1 arterial, 1 venflon, 1 CVP monitoring line Discharge paperwork as per unit procedure

Appendix.

Immunosuppression pathways

1) Standard

Tacrolimus Oral 0.075mg/kg/day in 2 divided doses po/ng bd- starts morning after surgery

Tacrolimus levels done Mon, Wed, Fri

Azathioprine 1mg/kg/day Oral day after transplant (rounded to nearest 25mg e.g. 80kg patient = 75mg/day)

2) Renal sparing (used if renal impairment (eGFR < 30 or creatinine > 150) OR blood loss >10 L in theatre.

Basiliximab 20mg Day 0 (day of OLT- check if has been given in theatre) and day 4 MMF 500mg bd IV (same dose as PO)

Withhold Tacrolimus until Day 7

No Azathioprine